Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Marco Basset, MD, Irene Defrancesco, MD, Paolo Milani, MD, Sara Rattotti, MD, Andrea Foli, MD, Marzia Varettoni, MD, Alessandro Corso, MD, Marco Paulli, Giampaolo Merlini, MD, Luca Arcaini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2018-99-118161

Published: 2018

Journal Articles

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Paolo Milani, MD, Marco Basset, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD

Blood (2018) 132 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2018-99-118108

Published: 2018

Journal Articles

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

Giovanni Palladini, MDPhD, Paolo Milani, MD, Marco Basset, MD, Francesca Russo, MD, Andrea Foli, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 4346.

https://doi.org/10.1182/blood.V130.Suppl_1.4346.4346

Published: 2017

Journal Articles

N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is an Independent Prognostic Factor for Overall Survival in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Paolo Milani, MD, Morie A. Gertz, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD, Martha Q Lacy, MD, Francis K Buadi, MD, Shaji K Kumar, MD, Suzanne R. Hayman, MD, Nelson Leung, MD, David Dingli, MD, John A. Lust, MD PhD, Yi Lin, MD PhD, Prashant Kapoor, MD, Ronald S. Go, MD, Yi L. Hwa, DNP, Steven Zeldenrust, MD, Robert A Kyle, MD, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2017) 130 (Supplement 1): 4349.

https://doi.org/10.1182/blood.V130.Suppl_1.4349.4349

Published: 2017

Journal Articles

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Esther Imperlini, PhD, Massimiliano Gnecchi, MD PhD, Paola Rognoni, PhD, Eduard Sabidò, PhD, Maria Chiara Ciuffreda, Giovanni Palladini, MDPhD, Guadalupe Espadas, Giuseppina Palladini, Stefania Orrù, PhD, Paolo Milani, MD PhD, Stefano Perlini, MD PhD, Francesco Salvatore, MD PhD, Giampaolo Merlini, MD, Francesca Lavatelli, MD PhD

Blood (2017) 130 (Supplement 1): 4393.

https://doi.org/10.1182/blood.V130.Suppl_1.4393.4393

Published: 2017

Journal Articles

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Giovanni Palladini, MDPhD, Ute Hegenbart, Paolo Milani, MD, Marco Basset, MD, Christoph Kimmich, MD, Francesca Russo, MD, Tilman Bochtler, MD, Andrea Foli, MD, Giampaolo Merlini, MD, Stefan Schönland, MD

Blood (2017) 130 (Supplement 1): 1759.

https://doi.org/10.1182/blood.V130.Suppl_1.1759.1759

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

Journal Articles

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Murielle Roussel, MD, Anne-Marie Stoppa, MD, Aurore Perrot, MD, Lionel Karlin, MD, Bertrand Arnulf, MD PhD, Margaret Macro, MD, Antoine Huart, MD, Laurent Frenzel, MD PhD, Pierre Morel, MD, Eileen Boyle, MD, Veronique Dorvaux, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD, David Lavergne, PhD, Frank Bridoux, MD PhD, Arnaud Jaccard

Blood (2017) 130 (Supplement 1): 508.

https://doi.org/10.1182/blood.V130.Suppl_1.508.508

Published: 2017

NARROW

Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome

Hematologic Responses in Patients with Heavily Pretreated Light Chain Deposition Disease (LCDD) Receiving Daratumumab

Persisting Cardiac Dysfunction and Quality of Response Predict Survival in Patients with AL Amyloidosis Who Respond to Upfront Therapy

N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is an Independent Prognostic Factor for Overall Survival in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Liver Involvement and d FLC Level Affect Survival of Patients with Non-Cardiac Light Chain Amyloidosis: A European Study of 334 Patients

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only